利奈唑胺与万古霉素治疗耐甲氧西林金黄色葡萄球菌感染疗效及安全性荟萃分析

发布时间：2018-06-27 21:26

本文选题：利奈唑胺 + 万古霉素　；参考：《中华医院感染学杂志》2015年06期

【摘要】：目的系统评价利奈唑胺和万古霉素治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染的临床疗效及安全性。方法计算机检索Cochrane图书馆、PubMed、Embase、CNKI全文数据库、维普中文科技期刊数据库中2013年6月前发表关于利奈唑胺和万古霉素治疗MRSA感染的随机对照试验文献,并应用STATA软件进行统计分析。结果共纳入11篇文献,合计5 567例患者,MRSA所致肺炎者利奈唑胺组临床治愈率、细菌清除率均高于万古霉素组(P0.05);MRSA所致复杂性皮肤软组织感染(cSTTI)者采用利奈唑胺治疗临床治愈率、细菌清除率均高于万古霉素组(P0.05);利奈唑胺的肾功能不全、不良反应发生率均低于万古霉素(P0.05),消化系统不良反应高于万古霉素(P0.01)。结论对于MRSA所致的肺炎、cSTTI感染,利奈唑胺的临床及微生物疗效优于万古霉素。
[Abstract]:Objective to evaluate the efficacy and safety of linazolamide and vancomycin in the treatment of methicillin resistant Staphylococcus aureus (MRSA) infection. Methods We searched the CNKI full text database of PubMedbase in Cochrane Library and published the randomized controlled trials on the treatment of MRSA infection with linazolamide and vancomycin before June 2013 in the database of Chinese Journal of Science and Technology. Stata software was used for statistical analysis. Results the clinical cure rate and bacterial clearance rate of 5 567 patients with pneumonia caused by MRSA were higher than those of vancomycin group (P0.05) with complex skin and soft tissue infection (cSTTI). The clearance rate of bacteria was higher than that of vancomycin group (P0.05), and the incidence of adverse reactions was lower than that of vancomycin group (P0.05), and the adverse reaction of digestive system was higher than that of vancomycin group (P0.01). Conclusion in the treatment of MRSA induced pneumonia, the clinical and microbial efficacy of lenazolamide is better than vancomycin.
【作者单位】：泉州医学高等专科学校;福建医科大学附属泉州第一医院感染科;
【基金】：福建省医学创新基金资助项目(2012-CX-33)
【分类号】：R978.1

【相似文献】